QQ客服 官方微博 反馈留言

浏览/检索结果: 共10条，第1-10条 帮助 限定条件 发表日期：2021     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo 期刊论文 CANCER SCIENCE, 2021, 页码: 12 作者:  Liu, Yingqiang;  Lai, Mengzhen;  Li, Shan;  Wang, Yanan;  Feng, Fang 收藏  |  浏览/下载：60/0  |  提交时间：2022/01/18 C797S  epidermal growth factor receptor  fourth-generation EGFR TKI  non-small cell lung cancer  osimertinib resistance   A phase II study of tislelizumab plus chemotherapy in EGFR mutated advanced non-squamous NSCLC patients failed to EGFR TKI therapies: First analysis 期刊论文 ANNALS OF ONCOLOGY, 2021, 卷号: 32 作者:  Han, B.;  Tian, P.;  Zhao, Y.;  Yu, X.;  Guo, Q. 收藏  |  浏览/下载：30/0  |  提交时间：2022/01/10 Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model 期刊论文 ACTA PHARMACOLOGICA SINICA, 2021, 页码: 10 作者:   收藏  |  浏览/下载：17/0  |  提交时间：2022/01/04 furmonertinib  autoinduction  food effect  alkaline phosphatase  body weight  pharmacokinetics  modeling and simulation  NSCLC   Liquid chromatography-mass spectrometry based metabolic characterization of pleural effusion in patients with acquired EGFR-TKI resistance 期刊论文 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2021, 卷号: 202 作者:  Li, Na;  Mao, Weimin;  Gao, Yun;  Wang, Ding;  Song, Zhengbo 收藏  |  浏览/下载：47/0  |  提交时间：2021/08/31 Lung cancer  EGFR-TKI  Resistance  Pleural effusion  Metabolomics  Biomarker   D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156). 期刊论文 CANCER RESEARCH, 2021, 卷号: 81 作者:  Lu, Shun;  Zhang, Yiping;  Zhang, Guojun;  Zhou, Jianying;  Cang, Shundong 收藏  |  浏览/下载：56/0  |  提交时间：2021/11/01 The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer 期刊论文 TRANSLATIONAL CANCER RESEARCH, 2021, 卷号: 10 作者:  Pan, Guoqiang;  Chen, Kaiyan;  Yu, Xiaoqing;  Sheng, Jiamin;  Fan, Yun 收藏  |  浏览/下载：35/0  |  提交时间：2021/11/01 Non-small cell lung cancer (NSCLC)  T790M abundance  droplet digital PCR (ddPCR)  next generation sequencing (NGS)  osimertinib   Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells 期刊论文 THORACIC CANCER, 2021, 页码: 9 作者:  Zhang, Mi;  Quan, Haitian;  Fu, Li;  Li, Yun;  Fu, Haoyu 收藏  |  浏览/下载：18/0  |  提交时间：2021/05/24 EGFR‐  mutant non‐  small cell lung cancer  famitinib  HS‐  10296  multi‐  targeted tyrosine kinase inhibitor  third‐  generation EGFR inhibitor   Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies 期刊论文 EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021 作者:  Wang, Zeng;  Jiang, Liyu;  Yan, Hao;  Xu, Zhifei;  Luo, Peihua 收藏  |  浏览/下载：19/0  |  提交时间：2021/04/26 Adverse events  chronic myeloid leukemia  management  mechanisms  molecular target  nilotinib   Biomimetic codelivery overcomes osimertinib-resistant NSCLC and brain metastasis via macrophage-mediated innate immunity 期刊论文 JOURNAL OF CONTROLLED RELEASE, 2021, 卷号: 329, 页码: 1249-1261 作者:  Zhao, Pengfei;  Zhang, Jiaxin;  Wu, Aihua;  Zhang, Meng;  Zhao, Yuge 收藏  |  浏览/下载：107/0  |  提交时间：2021/05/24 Brain targeting delivery  Tumor-associated macrophage  Osimertinib resistance  Brain metastasis  Innate immunity  Combination therapy   A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib 期刊论文 CLINICAL LUNG CANCER, 2021, 卷号: 22 作者:  Chen, Kaiyan;  Zhang, Fanrong;  Pan, Guoqiang;  Sheng, Jiamin;  Ye, Junyi 收藏  |  浏览/下载：26/0  |  提交时间：2021/03/15 Crizotinib  MET  Non-small-cell lung cancer  RET  Resistance